2cureX, pioneers of 3D microtumors in cancer therapy selection, are focused on improving the outcomes of cancer treatment.
Until today, there has been no functional means to evaluate the most efficacious form of cancer treatment for the individual patient. Up to 50% of first line treatments of metastatic colorectal cancer are ineffective mainly due to tumor resistance, causing a measurable burden on clinic resources and immeasurable patient suffering.
With the IVD CE validated IndiTreat® Sensitivity Test, you can now test cancer treatments on patient derived microtumors in order to:
- Predict tumor resistance and sensitivity to cancer drugs
- Select the most appropriate treatment, in accordance with guidelines or off-label
- Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
IndiTreat® is a useful complement to the advances achieved in individual patient genomic characterization of tumors.
IndiTreat® is available for all EU registered clinics and laboratories and is amenable to automation.
2cureX are based in Copenhagen, Denmark with a subsidiary in Hamburg, Germany.
2cureX are listed on Nasdaq First North Growth Market (symbol: 2CUREX)
October 21, 2021
Presentation by Henrik Harling (CMO 2cureX) at the 17. National Congress of Digestive Cancers (Viseu, Portugal)
November 15, 2021
Presentation by Ole Thastrup (CSO 2cureX) at the TechConnect Europe Innovation Conference & Expo (Malmø, Sweden)
November 25, 2021
Q3 2021 Interim Report released
February 24, 2022
Year-End Report 2021